```html

Eosinophilic Myocarditis – A Patient‑Friendly Medical Guide

Overview

Eosinophilic myocarditis (EM) is a rare form of heart muscle inflammation (myocarditis) in which an abnormal accumulation of eosinophils—a type of white blood cell involved in allergic reactions and parasitic infections—invades the myocardium. The eosinophils release toxic granules that damage heart muscle fibers, leading to impaired contraction, arrhythmias, and sometimes rapid progression to heart failure.

Who it affects: EM can occur at any age but has a biphasic distribution:

• Children and adolescents (often linked to hypersensitivity reactions to medications or infections).
• Adults aged 30‑60 years (commonly associated with systemic eosinophilic disorders, drug reactions, or hematologic malignancies).

Prevalence: Precise incidence is unknown because EM is often under‑diagnosed. Estimates from population‑based studies suggest it accounts for <1‑2% of all myocarditis cases, translating to roughly <10‑15 cases per million people per year in the United States<sup>[1] CDC, 2023</sup>. Despite its rarity, EM carries a higher mortality risk than “typical” lymphocytic myocarditis if not identified early.

Symptoms

Symptoms can be subtle at first and may mimic viral flu, asthma, or other cardiac conditions. Below is a comprehensive list with brief explanations:

• Chest pain or pressure – Often sharp, pleuritic, or radiating to the left arm; may worsen with deep breaths.
• Shortness of breath (dyspnea) – Usually progressive, especially on exertion or when lying flat (orthopnea).
• Palpitations – Sensation of rapid, irregular, or skipped heartbeats; can be due to arrhythmias caused by inflamed tissue.
• Fatigue & weakness – Result from reduced cardiac output and systemic inflammation.
• Fever & chills – Common when EM follows an infection or drug hypersensitivity.
• Peripheral edema – Swelling of ankles, feet, or abdomen indicating fluid buildup.
• Syncope or near‑syncope – Transient loss of consciousness caused by arrhythmias or low blood pressure.
• Unexplained weight loss – May accompany systemic eosinophilic disorders (e.g., Churg‑Strauss syndrome).
• Skin rash or hives – Suggests an allergic or drug‑triggered cause.
• Abdominal pain – Can be a manifestation of eosinophilic infiltration of other organs (e.g., gastrointestinal tract).
• Blood in stool or urine – Rare, but indicates eosinophilic involvement of the gastrointestinal or renal system.

In severe cases, patients present with cardiogenic shock (low blood pressure, cold extremities, altered mental status) or sudden cardiac death due to malignant ventricular arrhythmias.

Causes and Risk Factors

Eosinophilic myocarditis is not a single disease; it is a pathological pattern that can arise from several underlying conditions.

Primary Causes

• Drug hypersensitivity reactions – Antibiotics (e.g., vancomycin, penicillins), anti‑epileptics (e.g., carbamazepine), and certain NSAIDs are common triggers.
• Parasitic infections – Helminths such as Trichinella spiralis, Schistosoma, and Strongyloides can provoke marked eosinophilia.
• Systemic eosinophilic disorders – Including:
  • Hypereosinophilic syndrome (HES)
  • Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg‑Strauss)
  • Eosinophilic leukemia
• Idiopathic – In ~30‑40% of cases, no identifiable trigger is found after exhaustive work‑up.

Risk Factors

• History of allergic disease (asthma, allergic rhinitis, drug allergy).
• Recent exposure to a new medication or vaccine within the past 2‑4 weeks.
• Residence or travel to areas endemic for parasitic infections.
• Underlying hematologic malignancy (e.g., eosinophilic leukemia, lymphoma).
• Male gender appears slightly more common in adult cohorts (≈60% male).<sup>[2] Cleveland Clinic, 2022</sup>

Diagnosis

Diagnosing EM requires a high index of suspicion because routine tests for “ordinary” myocarditis may miss eosinophilic infiltration.

Step‑by‑step diagnostic pathway

1. Clinical evaluation – Detailed history (drug exposure, travel, allergic conditions) and physical exam (heart murmurs, rubs, signs of heart failure).
2. Basic laboratory tests – CBC with differential (eosinophil count >0.5 ×10⁹/L is a red flag), cardiac biomarkers (troponin I/T, CK‑MB), ESR/CRP.
3. Electrocardiogram (ECG) – May show nonspecific ST‑T changes, low voltage, or arrhythmias (ventricular premature beats, atrial fibrillation).
4. Echocardiography – Evaluates ventricular function, wall thickness, pericardial effusion; in EM, one may see thickened ventricular walls with reduced ejection fraction.
5. Cardiac magnetic resonance imaging (CMR) – The preferred non‑invasive tool; T2‑weighted images show edema, and late gadolinium enhancement (LGE) patterns are often sub‑epicardial or mid‑myocardial, suggesting inflammation.
6. Endomyocardial biopsy (EMB) – Gold standard. Histology reveals dense eosinophilic infiltrates, myocardial necrosis, and occasional granule‑filled eosinophils. Immunohistochemistry can differentiate from other infiltrative diseases.
7. Additional investigations – Parasitology stool exams, serologies (e.g., Toxocara, Strongyloides), ANA/ANCA panels, and genetic testing for clonal eosinophilia when HES is suspected.

Key diagnostic tip: In a patient with unexplained myocarditis and peripheral eosinophilia > 1,500 cells/µL, early consideration of EM and prompt EMB can dramatically improve outcomes.

Treatment Options

Management combines rapid suppression of eosinophilic inflammation and standard heart‑failure therapy. Treatment is typically individualized based on etiology, severity, and comorbidities.

1. Immunosuppressive/Anti‑inflammatory Therapy

• Corticosteroids – First‑line. Prednisone 1 mg/kg/day (or methylprednisolone 1 g IV daily for 3‑5 days in fulminant cases) then taper over 4‑6 weeks. Most patients show clinical and echocardiographic improvement within days.<sup>[3] Mayo Clinic, 2021</sup>
• Adjunctive agents – May be added if steroids alone are insufficient or for steroid‑sparing:
  • Azathioprine* or Mycophenolate mofetil* – 2‑3 mg/kg/day or 1‑2 g/day respectively.
  • Interleukin‑5 inhibitors* (e.g., mepolizumab, benralizumab) – Emerging data (small case series) show benefit in refractory HES‑related EM.

2. Targeted Treatment of Underlying Cause

• Drug removal – Immediate cessation of the offending medication.
• Antiparasitic therapy – Albendazole, ivermectin, or praziquantel depending on the parasite.
• Oncologic therapy – Tyrosine‑kinase inhibitors (e.g., imatinib) for PDGFRA‑positive HES.
• Biologic agents – Anti‑IL‑5 for EGPA; rituximab for ANCA‑positive vasculitis.

3. Standard Heart‑Failure & Arrhythmia Management

• ACE inhibitors or ARBs, beta‑blockers, and mineralocorticoid receptor antagonists (guideline‑directed medical therapy).
• Diuretics for volume overload.
• Anticoagulation if left‑ventricular thrombus is present (≈10‑15% of EM cases).
• Implantable cardioverter‑defibrillator (ICD) for patients with sustained ventricular tachycardia or significant scar on CMR.

4. Mechanical Support (for severe, fulminant cases)

• Intra‑aortic balloon pump (IABP) or ventricular assist device (VAD) as a bridge to recovery.
• Extracorporeal membrane oxygenation (ECMO) in cardiogenic shock refractory to pharmacologic therapy.

5. Lifestyle & Rehabilitation

• Gradual, physician‑supervised cardiac rehabilitation after acute phase.
• Low‑sodium diet, fluid restriction (if heart failure), and avoidance of known allergens or triggering drugs.

Living with Eosinophilic Myocarditis

Even after acute treatment, many patients require long‑term monitoring and lifestyle adjustments.

Daily Management Tips

• Medication adherence – Take steroids and any steroid‑sparing agents exactly as prescribed; never stop abruptly.
• Regular follow‑up – Cardiology visits every 3‑6 months initially, with ECG, echo, and blood eosinophil counts.
• Symptom diary – Record chest pain, palpitations, weight changes, and breathlessness; share with your doctor.
• Vaccinations – Stay up‑to‑date (influenza, COVID‑19, pneumococcal); discuss timing with your physician if you are on high‑dose steroids.
• Exercise – Start with low‑impact activities (walking, stationary cycling) and progress under supervision; avoid extreme exertion that triggers chest discomfort.
• Dietary considerations – Emphasize heart‑healthy foods (omega‑3 rich fish, fruits, vegetables) and limit saturated fats and processed salts.
• Allergy awareness – Keep a list of known drug or environmental allergies; wear medical alert jewelry if you have a drug hypersensitivity history.
• Mental health – Chronic cardiac disease can be stressful; consider counseling or support groups.

Prevention

Because many triggers are identifiable, primary prevention focuses on minimizing exposure:

• Medication vigilance – Inform all healthcare providers of prior drug reactions; prefer alternative agents when possible.
• Travel & food safety – Cook meat thoroughly, avoid raw fish in endemic regions, and practice good hand hygiene to reduce parasitic infection risk.
• Control of eosinophilic disorders – Early diagnosis and treatment of HES, EGPA, or allergic diseases can prevent cardiac involvement.
• Regular health screenings – CBC with differential annually for patients with known eosinophilic conditions; rising eosinophil counts warrant prompt evaluation.

Complications

If EM is not recognized or treated promptly, the inflammatory process can lead to serious, sometimes irreversible damage:

• Restrictive cardiomyopathy – Fibrotic remodeling limits ventricular filling, causing chronic heart failure.
• Dilated cardiomyopathy – Persistent inflammation weakens myocardium, leading to chamber dilation.
• Thromboembolic events – Intracardiac thrombus formation can cause stroke, systemic emboli, or pulmonary embolism.
• Life‑threatening arrhythmias – Ventricular tachycardia/fibrillation may cause sudden cardiac death.
• Multi‑organ eosinophilic infiltration – Kidneys, lungs, and nervous system can be involved, worsening overall prognosis.
• Relapse – Up to 20% of patients experience recurrence, especially if underlying eosinophilic disease remains uncontrolled.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe chest pain that does not improve with rest.
• Rapid, irregular heartbeat or a feeling of “fluttering” in the chest.
• Shortness of breath at rest or worsening suddenly.
• Fainting, light‑headedness, or loss of consciousness.
• Sudden swelling of the legs, abdomen, or severe sudden weight gain (signs of fluid overload).
• Persistent high fever (>38.5 °C) with chills, especially after a new medication or travel.
• Signs of a stroke – facial droop, arm weakness, speech difficulty.

These symptoms may indicate cardiac arrest, severe arrhythmia, or cardiogenic shock, which require immediate lifesaving interventions.

---

References

1. Centers for Disease Control and Prevention. Myocarditis and Pericarditis. Updated 2023.
2. Cleveland Clinic. Eosinophilic Myocarditis: Clinical Features and Management. 2022.
3. Mayo Clinic Proceedings. Corticosteroid therapy in eosinophilic myocarditis – outcomes and recommendations. 2021.
4. World Health Organization. Guidelines for Diagnosis and Treatment of Heart Failure. 2022.
5. National Institutes of Health, National Heart, Lung, and Blood Institute. Cardiovascular Disease in the Young. 2021.

```